pipeline-prospector-insert-v1
X

Find Clinical Drug Pipelines for Sleep

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Reboxetine

            Therapeutic Area: Sleep

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Axsome Therapeutics

            Deal Size: $331.0 million Upfront Cash: $3.0 million

            Deal Type: Licensing Agreement January 13, 2020

            Details:

            Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which xpands Axsome’s pipeline with new Phase 3-stageesreboxetine product candidate for fibromyalgia

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): JZP-258

            Therapeutic Area: Sleep

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            The submission is based on a Phase 3 global randomized-withdrawal, multicenter study that demonstrated the efficacy and safety of JZP-258 in the treatment of narcolepsy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Mazindol

            Therapeutic Area: Sleep

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: NLS Pharmaceutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 13, 2020

            Details:

            NLS Pharmaceutics entered a collaboration to develop mazindol (MZD) CR product candidates for the treatment of narcolepsy and ADHD utilizing Adare’s proprietary modified release technologies.